Clinical Trials Directory

Trials / Completed

CompletedNCT00838461

Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016

Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (estimated)
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

This is intended to provide an initial safety assessment of HSD-016 and also to evaluate how the drug is absorbed and eliminated and its effect on the body in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGHSD-016
DRUGplacebo

Timeline

Start date
2009-03-01
Primary completion
2009-06-01
Completion
2009-06-01
First posted
2009-02-06
Last updated
2009-08-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00838461. Inclusion in this directory is not an endorsement.

Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016 (NCT00838461) · Clinical Trials Directory